Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases.
[benign recurrent intrahepatic cholestasis]
Human
BSEP
(
ABCB
11
)
mutations
are
the
molecular
basis
for
at
least
three
clinical
forms
of
liver
disease
,
progressive
familial
intrahepatic
cholestasis
type
2
(
PFIC
2
)
,
benign
recurrent
intrahepatic
cholestasis
type
2
(
BRIC
2
)
,
and
intrahepatic
cholestasis
of
pregnancy
(
ICP
)
.
To
better
understand
the
pathobiology
of
these
disease
phenotypes
,
we
hypothesized
that
different
mutations
may
cause
significant
differences
in
protein
defects
.
Therefore
we
compared
the
effect
of
two
PFIC
2
mutations
(
D
482
G
,
E
297
G
)
with
two
BRIC
2
mutations
(
A
570
T
and
R
1050
C
)
and
one
ICP
mutation
(
N
591
S
)
with
regard
to
the
subcellular
localization
,
maturation
,
and
function
of
the
rat
Bsep
protein
.
Bile
salt
transport
was
retained
in
all
but
the
E
297
G
mutant
.
Mutant
proteins
were
expressed
at
reduced
levels
on
the
plasma
membrane
of
transfected
HEK
293
cells
compared
with
wild-
type
(
WT
)
Bsep
in
the
following
order
:
WT
>
N
591
S
>
R
1050
C
approximately
A
570
T
approximately
E
297
G
>
D
482
G
.
Total
cell
protein
and
surface
protein
expression
were
reduced
to
the
same
extent
,
suggesting
that
trafficking
of
these
mutants
to
the
plasma
membrane
is
not
impaired
.
All
Bsep
mutants
accumulate
in
perinuclear
aggresome-like
structures
in
the
presence
of
the
proteasome
inhibitor
MG-
132
,
suggesting
that
mutations
are
associated
with
protein
instability
and
ubiquitin-dependent
degradation
.
Reduced
temperature
,
sodium
butyrate
,
and
sodium
4
-
phenylbutyrate
enhanced
the
expression
of
the
mature
and
cell
surface
D
482
G
protein
in
HEK
293
cells
.
These
results
suggest
that
the
clinical
phenotypes
of
PFIC
2
,
BRIC
2
,
and
ICP
may
directly
correlate
with
the
amount
of
mature
protein
that
is
expressed
at
the
cell
surface
and
that
strategies
to
stabilize
cell
surface
mutant
protein
may
be
therapeutic
.
Diseases
Validation
Diseases presenting
"intrahepatic cholestasis"
symptom
benign recurrent intrahepatic cholestasis
zellweger syndrome
This symptom has already been validated